Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
NCT07720193 Etoposide Advanced Neuroendocrine Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07720193 clinical trial report covering Etoposide, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07719023 GDC-3280 Idiopathic Pulmonary Fibrosis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07719023 clinical trial report covering GDC-3280, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07720271 Zenagamtide Obesity Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07720271 clinical trial report covering Zenagamtide, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07723248 Enzalutamide Metastatic castration-resistant prostate cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07723248 clinical trial report covering Enzalutamide, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07721961 MI-078 Depression, Postpartum Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07721961 clinical trial report covering MI-078, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07722494 Bevacizumab biosimilar (Innovent Biologics) Advanced Colorectal Adenocarcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07722494 clinical trial report covering Bevacizumab biosimilar (Innovent Biologics), Phase 3, endpoints, sponsor, geography, readout timing and developm
Latest Hotspot
8 min read
NCT07722962 Oremepermin alfa acute spinal cord injury Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07722962 clinical trial report covering Oremepermin alfa, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07724132 Metformin Hydrochloride Alzheimer Disease Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07724132 clinical trial report covering Metformin Hydrochloride, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07723469 SRG-514 Triple Negative Breast Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07723469 clinical trial report covering SRG-514, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07723976 Cannabidiol Developmental and epileptic encephalopathy Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07723976 clinical trial report covering Cannabidiol, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07722988 Roxadustat Anemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07722988 clinical trial report covering Roxadustat, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
CTR20262842 Nemolizumab Dermatitis, Atopic Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
CTR20262842 clinical trial report covering Nemolizumab, Phase 3, endpoints, sponsor, geography, readout timing and development white space.